Skip to main content

PsA BIOnd

Study details

Study purpose: Observational cohort study of Guselkumab (Tremfya) and anti- IL17 therapy in PSA
Symptoms/Diagnose: PsA
Disease phase: Active PsA
Indication/Medication: Start Guselkumab or anti-IL17 (Secukinumab, Ixekizumab) therapy

In short

Key points

SpA and pre-SpA

Diseases

Spondylarthritis

Committed staff members

  • Groothuizen, S. (Sam)

    • Contact us

    s.groothuizen@amsterdamumc.nl

    More studies

    View all

    3TR – Flare study

    3TR - Flare study

    Research on biomarkers for developing a flare in SLE

    • SLE
    • Systemic Lupus Erythematosus
    • Broens, B. (Bo)
    Read more
    IgG4 in vasculitis

    IgG4 in vasculitis

    IgG4/IgG RNA ratio as a disease activity marker in vasculitis

    • General
    • Vasculitis
    • Weele, L. van der (Linda)
    Read more
    FaMaLE

    FaMaLE

    Study of failing immune tolerance between mother and fetus as cause of pregnancy complications in SLE

    • SLE
    • Systemic Lupus Erythematosus
    • Dankers, W. (Wendy)
    Read more
    JAKARTA

    JAKARTA

    Evaluation effect of Filgotinib on heart through cardiac MRI/CT in RA

    • RA and pre-RA
    • Rheumatoid arthritis
    • Bas Dijkshoorn
    Read more
    Onderzoek not found.
    PsA BIOnd

    PsA BIOnd

    Observational cohort study of Guselkumab (Tremfya) and anti- IL17 therapy in PSA

    • SpA and pre-SpA
    • Spondylarthritis
    • Groothuizen, S. (Sam)
    Read more

    Leave a Reply